Transaction · 0001493152-26-040207

Pershing Edward

Pershing Edward, CEO, reported a transaction classified as exercise at PROVECTUS BIOPHARMACEUTICALS, INC. involving 11328.000000 shares for an estimated $0.00. Reported holdings after the transaction were 2924949.000000 shares. A 10b5-1 reference was not detected in the stored filing text.

exerciseSEC transaction code MCEO
PVCTPROVECTUS BIOPHARMACEUTICALS, INC.
Trade date
Aug 26, 2026
Filing date
Aug 26, 2026
View on SEC Insider profile
Estimated value$0Shares × reported price
Shares traded11.3k$0.00 per share
Holdings after2.92MDirect
% of reported position tradedUnavailableThis security and ownership context
How reported position traded is calculated

Not calculated for derivative securities.

Row-level estimate for this security and ownership context, not the insider’s complete portfolio. Joint ownership, other transactions in the filing, amendments and footnotes can affect interpretation.

PVCT price since this filing

Daily closing prices, with the filing date and available return windows
PVCT · Daily closing priceLoading daily prices…
Filing dateReturn windows appear as prices become available.
Pre-filing1mo ago1w ago1d ago
Returns since7d30d90d180d1y

Transaction facts

Stored Form 4 columns with their raw values

Derivative
Type
exercise
Code M
Identifier
0001493152-26-040207
Series D-1 Convertible Preferred Stock
Transaction date
Aug 26, 2026
Filed Aug 26, 2026, 06:20 PM · 0d delay
Shares
11,328 sh
$0.00 per share
Estimated value
$0
Computed from shares × price
Holdings after
2,924,949 sh
Direct

Filing signal explanations

Badges describe filing facts only — not predictions.

Cluster 14dRepeat 30dPattern $100kLarge $1.00M
Derivative Transaction Direct Ownership
Filing-only score

-6 points

Compact filing score computed from stored Form 4 facts. Version v1.

Mixed or weak signal

This filing has a negative filing-only score. It may be less informative as an insider-activity signal and needs extra context.

How this score is calculated
  • direct_ownership+6 points

    direct_or_indirect_ownership = D

    Direct ownership reports the insider's personal stake.
  • timely_filing+4 points

    reporting_delay_days = 0

    Filing reported within two business days of the transaction.
  • derivative_transaction-16 points

    is_derivative = true

    Derivative exercise rows are less discretionary than open-market purchases.
Read the scoring methodology

Signed filing-only points, not a probability or expected return. Version v1.

Reported relationships & other filings

Form 4 relationship flags and nearby filing context

Reported roles

CEO

Officer YesDirector Yes10% YesOther No
Footnotes & amended
  1. F1

    Each share of Series D-1 Preferred Stock is convertible into 10 shares of the Issuer's common stock, par value $0.001 per share ("Common Stock").

  2. F2

    The Series D-1 Convertible Preferred Stock will automatically convert into Common Stock on December 31, 2028, unless earlier converted into Common Stock in accordance with the terms of the Certificate…

  3. F3

    The Reporting Person could have voluntarily elected to convert the outstanding principal and interest of the 8% unsecured convertible promissory note (the "2025 Note") at any time while the 2025 Note…

  4. F4

    On August 26, 2026, the 2025 Note converted into 11,328 shares of Series D-1 Preferred Stock.

  5. F5F6(2 footnotes)

    The amount reported reflects an adjustment to correct a typographical error in a previously filed Form 4. This adjustment does not reflect a transaction by the Reporting Person.

Original filing · 0001493152-26-040207
Related transactions

0 other transactions

Same SEC filing
Recent company activity

0 recent txs

PVCT